m-BACOD

Oncology A 2^nd-generation combination chemotherapy regimen–MTX, bleomycin, Adriamycin-doxorubicin, cyclophosphamide, Oncovin–vincristine, dexamethosone

Mentioned in ?

CHOP DC

References in periodicals archive ?

Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD.

Survival in patients with oral and maxillofacial diffuse large B-cell lymphoma

Current regimens include half-dose chemotherapeutic agents such as methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-BACOD) with adjunctive use of hematopoietic growth factor (granulocyte-macrophage colony stimulating factor, GM-CSF, or granulocyte colony stimulating factor, G-CSF).[14,15] However, complete response occurs in ~65% of treated patients, with relapse in ~25% of these patients within 6 months.

Low dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection.